Cost-Effectiveness analysis of mammostrat®compared with oncotype DX®to inform the treatment of breast cancer

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2014, Pages 37-47

  Mislick, Kimberly ^a   Schonfeld, Warren ^b   Bodnar, Carolyn ^c   Tong, Kuo Bianchini ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Quorum Consulting Inc   (United States)

^c GE HEALTHCARE   (United Kingdom)

Author keywords

Assay; Breast cancer; Cost Effectiveness analysis; IVD; Mammostrat

Indexed keywords

ARTICLE; BIOASSAY; BREAST CANCER; CANCER RECURRENCE; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; MONTE CARLO METHOD; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

EID: 84892564805     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S53142     Document Type: Article

References (2)

1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
2. Ross DT, Kim CY, Tang G, et al. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res. 2008;14(20):6602-6609.